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Summary
Background Neurite outgrowth inhibitor A (Nogo-A) is thought to have a role in the pathophysiology of amyotrophic 
lateral sclerosis (ALS). A monoclonal antibody against Nogo-A showed a positive eff ect in the SOD1G93A mouse model 
of ALS, and a humanised form of this antibody (ozanezumab) was well tolerated in a fi rst-in-human trial. Therefore, 
we aimed to assess the safety and effi  cacy of ozanezumab in patients with ALS.
Methods This randomised, double-blind, placebo-controlled, phase 2 trial was done in 34 centres in 11 countries. 
Patients aged 18–80 years with a diagnosis of familial or sporadic ALS were randomly assigned (1:1), centrally 
according to a computer-generated allocation schedule, to receive ozanezumab (15 mg/kg) or placebo as intravenous 
infusions over 1 h every 2 weeks for 46 weeks, followed by assessments at week 48 and week 60. Patients and study 
personnel were masked to treatment assignment. The primary outcome was a joint-rank analysis of function (ALS 
Functional Rating Scale-Revised) and overall survival, analysed at 48 weeks in all patients who received at least one 
dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01753076, and with GSK-
ClinicalStudyRegister.com, NOG112264, and is completed.
Findings Between Dec 20, 2012, and Nov 1, 2013, we recruited 307 patients, of whom 303 were randomly assigned to 
receive placebo (n=151) or ozanezumab (n=152). The adjusted mean of the joint-rank score was –14·9 (SE 13·5) for 
the ozanezumab group and 15·0 (13·6) for the placebo group, with a least squares mean diff erence of –30·0 (95% CI 
–67·9 to 7·9; p=0·12). Overall, reported adverse events, serious adverse events, and adverse events leading to 
permanent discontinuation of study drug or withdrawal from study were similar between the treatment groups, 
except for dyspepsia (ten [7%] in the ozanezumab group vs four [3%] in the placebo group), depression (11 [7%] vs 
fi ve [3%]), and diarrhoea (25 [16%] vs 12 [8%]). Respiratory failure was the most common serious adverse event (12 [8%] 
vs seven [5%]). At week 60, the number of deaths was higher in the ozanezumab group (20 [13%]) than in the placebo 
group (16 [11%]), mainly as a result of respiratory failure (ten [7%] vs fi ve [3%]). Two deaths were considered related to 
the study drug (bladder transitional cell carcinoma in the ozanezumab group and cerebrovascular accident in the 
placebo group).
Interpretation Ozanezumab did not show effi  cacy compared with placebo in patients with ALS. Therefore, Nogo-A 
does not seem to be an eff ective therapeutic target in ALS.
Funding GlaxoSmithKline.
Introduction
Amyotrophic lateral sclerosis (ALS) is a neuro-
degenerative disorder characterised by progressive 
degeneration of motor neurons in the brain and spinal 
cord.1 In most patients, ALS progressively involves 
muscles, leading to weakness and ultimately death, 
typically as a result of respiratory failure.2 Most patients 
die within 5 years of symptom onset.3 The patho-
physiological mechanisms remain unconfi rmed, but 
pathogenic changes are considered to involve inter-
ference with protein degradation and defects in RNA 
processing.1 These changes lead to progressive cellular 
failure, disruption of axonal architecture and function, 
axonal retraction, and ultimately denervation of neurons 
or muscles.1 The processes of axonal retraction and 
denervation might be further modulated by axonal 
attraction and repellent systems, which are responsible 
for the development and stabilisation of the neuronal 
network.1 Oxidative stress, glutamate toxicity, mito-
chondrial dysfunction, autophagic dysfunction, and 
immune-infl ammatory responses have also been 
implicated in the pathogenesis of ALS.2
Only one approved drug, riluzole, has an eff ect, albeit 
small, on the survival of patients with ALS.2 Data from 
randomised controlled trials suggest that riluzole extends 
survival by a median of 2–3 months, whereas results from 
uncontrolled registry studies suggest prolongation of 
survival by up to 21 months.4 Although results 
from preclinical studies and many clinical trials were 
encouraging, no other treatments have shown any 
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eff ect on the disease course.5 Apart from riluzole, multi-
disciplinary palliative care remains the main management 
approach for ALS.2
Neurite outgrowth inhibitor A (Nogo-A) is a high-
molecular-weight transmembrane protein, initially 
identifi ed as a potent myelin-associated inhibitor of 
axonal growth expressed mostly by oligodendrocytes, 
that has been suggested to have a role in the 
pathophysiology of ALS.6,7 Nogo-A is expressed at very 
low levels in healthy skeletal muscle but is upregulated 
in the skeletal muscle of patients with ALS,6 and seems 
to be associated with disease severity.8 The link between 
Nogo-A and ALS was strengthened by the fi nding that 
Nogo-A was associated with neuromuscular junction 
denervation and rapid functional decline in patients with 
ALS.9 Nogo-A expression is also upregulated in the 
skeletal muscle of the superoxide dismutase 1 (SOD1) 
transgenic mutant mouse, a widely used model for ALS.10 
Exogenous overexpression of Nogo-A in the skeletal 
muscle of wild-type mice led to denervation and 
instability of the neuromuscular junction,11 whereas 
deletion of the Nogo-A gene in SOD1G86R mice resulted in 
a moderate but signifi cant increase in lifespan and was 
associated with a neuroprotective eff ect.11 These fi ndings 
suggested that Nogo-A expression in skeletal muscle 
could contribute to the pathology of ALS and that Nogo-A 
is a potential therapeutic target.
Ozanezumab (GSK1223249) is a humanised mono-
clonal antibody against Nogo-A that was well tolerated in 
a fi rst-in-human study.12 Although the study was not 
designed to assess effi  cacy, results for functional 
endpoints were numerically in favour of ozanezumab at 
the highest dose (two doses of 15 mg/kg given roughly 
2 weeks apart).12 In this phase 2 trial, we assessed the 
eff ect of ozanezumab on the function and survival of 
patients with ALS.
Methods
Study design
This randomised, double-blind, placebo-controlled, 
phase 2 trial was done in 34 centres across 11 countries 
(Australia, Belgium, Canada, France, Germany, Italy, 
Japan, South Korea, the Netherlands, the UK, and 
the USA). The protocol was approved by the relevant 
ethics committee in each country. The study was done and 
monitored in accordance with Good Clinical Practice and 
the guiding principles of the Declaration of Helsinki 2008.
Participants
We recruited patients aged 18–80 years with a diagnosis 
of familial or sporadic ALS (defi ned as meeting the 
possible, laboratory-supported probable, probable, or 
defi nite criteria for a diagnosis of ALS according to the 
revised World Federation of Neurology El Escorial 
criteria13) who had onset of muscle weakness no more 
than 30 months before the screening visit and slow vital 
capacity of at least 65% at screening (predicted for sex, 
age, ethnic origin, and height). Full study inclusion and 
exclusion criteria are listed in the appendix (p 1). Eligible 
patients were identifi ed in the clinic at each of the study 
sites and recruited into the study according to the 
protocol. All patients provided written informed consent.
Randomisation and masking
After an initial screening period, patients were enrolled by 
study investigators and randomly assigned (1:1) to receive 
ozanezumab or placebo at the second study visit (week 0). 
Patients were randomised centrally across all sites in 
accordance with a computer-generated randomisation 
schedule validated by GlaxoSmithKline. Anonymised 
patient numbers were provided to investigators via an 
interactive voice response system. Infusions were prepared 
by a non-masked pharmacist at the study site, and masking 
Research in context
Evidence before this study
We searched PubMed up to Feb 3, 2016, with the term 
“(nogo-a OR RTN4 OR “neurite outgrowth inhibitor”) AND 
(ALS OR motor neurone disease)” and no language restrictions. 
Evidence from mouse models of amyotrophic lateral sclerosis 
(ALS), together with molecular analysis of skeletal muscle from 
patients with ALS, suggests a role for neurite outgrowth 
inhibitor A (Nogo-A) in the pathophysiology of ALS. Results 
from a fi rst-in-human clinical study showed that ozanezumab, 
a humanised monoclonal antibody against Nogo-A, was well 
tolerated in patients with ALS. We did not identify any 
randomised controlled trials assessing the effi  cacy of 
ozanezumab or other drugs with this mechanism of action.
Added value of this study
This study was the fi rst randomised, placebo-controlled trial 
designed to assess the safety and effi  cacy of an anti-Nogo-A 
monoclonal antibody for the treatment of patients with ALS. 
We did not fi nd any evidence of effi  cacy of ozanezumab over 
placebo. The desired level of exposure to ozanezumab was 
achieved; therefore, the absence of effi  cacy was not thought 
to be related to suboptimal dosing. These results suggest the 
futility of further clinical testing of an anti-Nogo-A 
monoclonal antibody for the treatment of ALS.
Implications of all the available evidence
At present, only one approved drug, riluzole, has been shown to 
have a slight eff ect on the survival of patients with ALS. Thus, 
the identifi cation of new options for ALS treatment remains a 
priority for clinical research. 
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of infusion bags and drip chambers was achieved by 
covering with orange tape. Patients and all study personnel 
administering the interventions, assessing outcomes, and 
analysing data were masked to treatment assignment.
Procedures
We selected an ozanezumab dose regimen of 15 mg/kg 
once every 2 weeks for this study on the basis of analysis 
of drug biodistribution into muscle, co-localisation of 
Nogo-A with ozanezumab at the target site (ie, muscle 
cell membrane), plasma pharmacokinetic data, and the 
safety profi le from clinical and non-clinical studies.12,14,15 
Patients received ozanezumab or placebo as intravenous 
infusions over 1 h. A total of 24 infusions were planned, 
starting at the baseline visit (week 0) and then every 
2 weeks up to the last dose at week 46, followed by 
assessments at week 48 and week 60. Since this dosing 
regimen had not been tested in human beings previously, 
we used a two-part study design. In part A, a subgroup of 
24 patients had intensive safety monitoring during the 
fi rst four antibody infusions, with independent review of 
data before recruitment of the remaining patients for 
part B of the study (appendix). 
Outcomes
The primary outcome was a joint-rank analysis of function 
(ALS Functional Rating Scale-Revised [ALSFRS-R]) and 
overall survival at 48 weeks. The ALSFRS-R questionnaire 
was administered at clinic visits; for participants who were 
unable to attend the clinic, it could also be administered 
by telephone, thus reducing risk of missing data and 
allowing data collection from patients who had withdrawn 
from study treatment but who did not withdraw consent. 
Secondary effi  cacy outcomes were change from 
baseline in ALSFRS-R total score at week 48, monthly 
rate of decline in ALSFRS-R total score over 48 weeks, 
progression-free survival (with progression defi ned as at 
least a six-point decrease on ALSFRS-R) at week 48, 
overall survival (defi ned as time from randomisation 
until death or censoring) at week 48 and week 60, the 
proportion of responders to the Clinical Global 
Impression-Improvement Scale at week 48, and change 
from baseline in respiratory function (slow vital capacity) 
and muscle power (measured by hand-held 
dynamometry) at week 48. The secondary analysis of 
ALSFRS-R data was added at protocol amendment 
(May 29, 2013) to aid clinical interpretation of the 
results.16 The protocol amendment was made during 
recruitment for part B of the study (after safety data from 
part A of the study had been reviewed but before data 
analysis), and was documented and approved by the 
relevant ethics committees.
Additional secondary outcomes were change from 
baseline to week 48 in health outcomes (based on the 
EuroQol-Short Form 5-level version [EQ-5D-5L]) and the 
Amyotrophic Lateral Sclerosis Assessment Questionnaire 
(ALSAQ-40), plasma pharmacokinetics parameters of 
ozanezumab, and plasma concentrations of riluzole (to 
assess any pharmacokinetic interaction with ozanezumab). 
Safety assessments were the monitoring of serious 
adverse events, adverse events, disease-related events, 
routine laboratory tests (clinical chemistry and 
haematology), vital signs, and electrocardiograms 
(ECGs). Adverse events and disease-related events were 
coded according to the Medical Dictionary for Regulatory 
Activities coding system. Values for clinical laboratory 
assessments were compared with both the appropriate 
normal ranges and ranges of potential clinical concern. 
Any abnormal test result or other safety assessment 
judged by the investigator to be clinically signifi cant was 
recorded as an adverse event or a serious adverse event. 
Other safety measures included the primary cause of 
death, use of respiratory support (invasive or non-
invasive), occurrence of tracheostomies and gastros-
tomies, assessment of suicidal ideation and behaviour 
(measured by the Columbia-Suicide Severity Rating 
Scale) and possible suicidality-related adverse events, 
neurological examination, and immunogenicity 
(incidence of anti-ozanezumab antibodies and relation 
with pharmacokinetics, safety, and effi  cacy).
Patients who stopped treatment, but who did not 
withdraw consent to continue in the study, were 
encouraged to continue to provide ALSFRS-R and safety 
data up to week 48 via telephone contact, and mortality 
was monitored up to week 60. They were also requested 
to return for a follow-up immunogenicity visit roughly 
14 weeks after the last infusion.
Statistical analysis
We estimated that a sample size of 147 patients per group 
would provide roughly 86% power to detect a signifi cant 
diff erence in the primary outcome between the two groups 
at a two-sided alpha of 5%, with 80% power to detect a 
30% improvement in the rate of decline in ALSFRS-R and 
31% power to detect a 5% improvement in survival. These 
estimates were based on the following assumptions: the 
mean weekly rate of decline in ALSFRS-R was 0·235 with 
placebo and 0·165 with ozanezumab; the weekly rate of 
decline in ALSFRS-R had a variance of 0·044 in both 
groups; the within-individual variance in change in 
ALSFRS-R from baseline was 4; overall survival followed 
an exponential distribution in both groups, the 48-week 
mortality with placebo was 10%, and the absolute reduction 
in mortality with ozanezumab was 5%; the dropout rate 
(excluding death) of the ALSFRS-R was 20% in both 
groups; and the correlation between ALSFRS-R and overall 
survival for each individual was zero. Refi nements made 
to power calculations as part of the protocol amendment 
on May 29, 2013, indicated a slightly increased power (but 
still within 80–90%) and no change in sample size.
The joint-rank analysis of function (ALSFRS-R) and 
48-week survival was determined as follows. Briefl y, each 
patient was assigned a summary score based on pairwise 
comparisons against all other patients in the study at 
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week 48 (across both treatment groups). For each 
comparison, the patient scored + 1 if they had a better 
outcome (higher functional score at the last common 
visit or longer survival), 0 if no diff erence in outcome 
existed, or –1 if they had a worse outcome (lower 
functional score at the last common visit or shorter 
survival). Each patient’s summary score was calculated 
on the basis of the sum of each individual score. The 
mean total score of patients receiving ozanezumab was 
compared with that of patients receiving placebo. This 
analysis diff ers from the combined analysis of function 
and survival, as used in the EMPOWER study17 in ALS 
(published after the present study had commenced), in 
which the joint-rank score was ranked and then the mean 
rank was compared between groups.17,18
Effi  cacy and safety outcomes were analysed in the 
modifi ed intention-to-treat population, which comprised 
all randomised patients who received at least one dose of 
study drug. The concentrations of ozanezumab and 
riluzole (pharmacokinetics) were assessed in all patients 
who received at least one dose of the drug and from 
whom at least one plasma sample was analysed for the 
respective drug.
We used on-treatment data (ie, data collected up to 
21 days after the patient’s last infusion) for the modifi ed 
intention-to-treat population to analyse the primary 
outcome. We included retrieved follow-up data (ie, data 
collected more than 21 days after the patient’s last infusion, 
typically by telephone) in additional, separate, prespecifi ed 
analyses of joint-rank scores, ALSFRS-R, and survival. 
Data were adjusted for baseline ALSFRS-R total score, 
riluzole use, country, and treatment assignment. We used 
SAS, version 9.2, for statistical analyses.
An independent, unmasked data-monitoring committee 
reviewed safety data, including adverse events, laboratory 
results, ECGs, and other safety assessments at regular 
intervals (roughly every 3 months) throughout the study.
This study is registered with ClinicalTrials.gov, number 
NCT01753076, and with GSK-ClinicalStudyRegister.com, 
NOG112264.
Role of the funding source
The funder of the study was involved in study design, 
funding of the participating centres, data analysis, and 
writing and funding of the manuscript. The 
corresponding author had full access to all the data in the 
study and had fi nal responsibility for the decision to 
submit for publication.
Results
We enrolled 307 patients, of whom 303 were randomised 
and included in the effi  cacy and safety analyses. Between 
Dec 20, 2012, and Jan 29, 2013, 24 patients entered into 
part A of the study, of whom 12 received ozanezumab 
and 12 received placebo. The independent data-
monitoring committee did not identify any substantial 
safety concerns, and 279 patients entered into part B of 
the study between May 15, 2013, and Nov 1, 2013. Overall, 
151 patients received placebo and 152 received 
ozanezumab (fi gure 1). 216 patients completed the 
follow-up visit 14 weeks after the last dose and provided 
data for at least 60 weeks after the baseline assessment. 
Demographic and baseline characteristics were well 
balanced between the two treatment groups (table 1).
At 48 weeks, the adjusted mean of the joint-rank score of 
function and survival was 15·0 (SE 13·6) in the placebo 
group and –14·9 (13·5) in the ozanezumab group, with a 
least squares means diff erence (ozanezumab minus 
placebo) of –30·0 (95% CI –67·9 to 7·9; p=0·12; table 2). 
For all secondary effi  cacy outcomes, the adjusted means 
were slightly higher, but non-signifi cantly so, in the 
placebo group than in the ozanezumab group (table 2, 
appendix). The adjusted mean diff erence between the 
ozanezumab group and the placebo group in change from 
baseline in ALSFRS-R total score at week 48 was –1·3 
(95% CI –3·1 to 0·4; p=0·14; fi gure 2A; table 2).
Survival outcomes were not signifi cantly diff erent 
between the treatment groups (fi gure 2B). At week 48, 
six (4%) patients in the placebo group and eight (5%) 
patients in the ozanezumab group had died. Inclusion of 
retrieved follow-up data showed that nine (6%) patients in 
the placebo group and 15 (10%) patients in the ozanezumab 
Figure 1: Trial profi le
*The patient did not receive the study drug. †Reasons for withdrawal were adverse events (n=17), lack of effi  cacy (n=3), 
stopping criteria reached (n=1), lost to follow-up (n=2), physician decision (n=4), and withdrawal of consent (n=14). 
‡Reasons for withdrawal were adverse events (n=18), lack of effi  cacy (n=1), lost to follow-up (n=1), physician decision 
(n=2), and withdrawal of consent (n=24). §These patients withdrew from study drug but continued to provide data for 
the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised and any relevant safety information by telephone up 
to week 48 and completed their follow-up visit.
106 completed all doses up to week 46
100 patients completed the trial
152 patients assigned to ozanezumab
46 withdrew from ozanezumab
40 withdrew from study‡
6 provided data to week 48§
6 withdrew from study‡
115 completed all doses up to week 46
108 patients completed the trial
151 patients assigned to placebo
303 randomised
307 patients enrolled
4 excluded
2 did not meet inclusion criteria
1 adverse event*
1 withdrew consent
36 withdrew from placebo
34 withdrew from study†
2 provided data to week 48§
7 withdrew from study†
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group had died at week 48, with a hazard ratio (HR) of 1·30 
(95% CI 0·56–3·01; p=0·54). Progression-free survival at 
week 48 was 30·8% (23·0–38·6) in the placebo group and 
28·5% (21·1–35·9) in the ozanezumab group (HR 1·07, 
0·81–1·42; p=0·64). At week 60, 16 (11%) patients in the 
placebo group and 20 (13%) patients in the ozanezumab 
group had died (HR 1·03, 0·53–2·01; p=0·92; appendix). 
Since the proportionality assumptions were questionable 
for the Cox proportional hazard model because of the low 
number of events, we did a post-hoc analysis using the 
Kolmogorov-Smirnov test, the p values of which did not 
alter the interpretation of the results (appendix). No 
diff erence was seen between the placebo and ozanezumab 
groups for the health outcomes (change in ALSAQ–40 
total score and EQ-5D-5L; appendix).
Plasma ozanezumab concentrations were consistent 
with those predicted before the study—ie, concentrations 
increased steadily with each dose and steady state was 
reached by week 12 (ie, dose 7). No evidence of change in 
ozanezumab elimination or clearance was seen 
(appendix). Plasma riluzole concentrations generally 
remained consistent with baseline values over the course 
of the study, with no evidence of change in elimination or 
clearance (appendix).
Overall, reported adverse events, serious adverse events, 
and adverse events leading to permanent discontinuation 
of study drug or withdrawal from study were similar 
between the treatment groups (table 3). Of 36 deaths 
reported, fi ve (two in the ozanezumab group and three in 
the placebo group) occurred after follow-up contact, 
which was outside the timeframe specifi ed for data 
collection of serious adverse events. No associated serious 
adverse events were reported for these fi ve deaths, and all 
were judged by investigators to be due to ALS. The 
31 remaining deaths occurred during the treatment or 
follow-up period (table 3). Two deaths were considered 
related to the study drug (bladder transitional cell 
carcinoma in the ozanezumab group and cerebrovascular 
accident in the placebo group). The higher number of 
deaths in the ozanezumab group than in the placebo 
group was attributable to a higher frequency of respiratory 
failure (ten [7%] vs fi ve [3%]; appendix). 47 (31%) patients 
in the ozanezumab group had at least one serious adverse 
event, compared with 46 (30%) in the placebo group 
(table 3). Respiratory failure was the most common 
serious adverse event, reported in 12 (8%) patients in the 
ozanezumab group and seven (5%) in the placebo group. 
Three drug-related non-fatal serious adverse events 
(anaemia, appendicitis, and pulmonary embolism) were 
reported in the ozanezumab group, and two such events 
(unilateral blindness and thrombosis) were reported in 
the placebo group. The most common adverse events 
(reported by >10% of the overall population) were falls 
(125 [41%] patients), nasopharyngitis (67 [22%]), headache 
(55 [18%]), cough (37 [12%]), diarrhoea (37 [12%]), and 
constipation (36 [12%]; appendix). Some adverse events 
were roughly twice as frequent in the ozanezumab 
Placebo group 
(n=151)
Ozanezumab group 
(n=152)
Age, years
Mean 55·5 (11·0) 55·7 (10·4)
18–64 115 (76%) 120 (79%)
65–74 34 (23%) 28 (18%)
75–81* 2 (1%) 4 (3%)
Sex
Men 97 (64%) 103 (68%)
Women 54 (36%) 49 (32%)
Ethnic origin
Not Hispanic or Latino 150 (99%) 149 (98%)
Hispanic or Latino 1 (1%) 3 (2%)
Height, cm 170·6 (9·2) 171·2 (10·3)
Weight, kg 72·8 (14·1) 75·1 (16·4)
Age at muscle weakness 
onset, years
54·4 (11·0) 54·6 (10·3)
Site of disease onset
Upper limb or limbs 69 (46%) 63 (41%)
Lower limb or limbs 44 (29%) 46 (30%)
Both upper and lower limbs 5 (3%) 6 (4%)
Bulbar 32 (21%) 33 (22%)
Other 1 (1%) 4 (3%)
Time to diagnosis from onset 
of muscle weakness, months
8·0 (5·8) 8·8 (5·6)
Time since muscle weakness 
onset, months
17·9 (6·6) 18·5 (6·3)
Time since initial diagnosis, 
months
9·8 (7·2) 9·6 (6·7)
Age at initial diagnosis, years 55·1 (11·1) 55·3 (10·4)
Type of disease
Sporadic 139 (92%) 143 (94%)
Familial 12 (8%) 9 (6%)
Certainty of diagnosis
Possible 11 (7%) 14 (9%)
Laboratory-supported 
probable
25 (17%) 22 (14%)
Probable 67 (44%) 72 (47%)
Defi nite 48 (32%) 44 (29%)
Number of regions† involved
One 26 (17%) 22 (14%)
Two 68 (45%) 62 (41%)
Three 38 (25%) 51 (34%)
Four 19 (13%) 17 (11%)
Percentage predicted slow 
vital capacity
95·7% (18·0) 93·3% (17·5)
Riluzole use 132 (87%) 131 (86%)
Riluzole plasma 
concentration, ng/mL
122·4 (100·9) 103·3 (99·5)
ALSFRS-R total score 38·4 (5·1) 37·7 (5·5)
Data are mean (SD) or n (%). ALSFRS-R=Amyotrophic Lateral Sclerosis Functional 
Rating Scale-Revised. *Because exact dates of birth were not collected to protect 
anonymity, the oldest patient could have been aged 80 years or 81 years. 
†Brainstem, cervical, thoracic, or lumbosacral spinal cord. 
Table 1: Demographic and clinical baseline characteristics
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group than in the placebo group—for example, dyspepsia 
(ten [7%] vs four [3%]), depression (11 [7%] vs fi ve [3%]), 
and diarrhoea (25 [16%] vs 12 [8%]). No serious adverse 
events related to depression were reported in either 
group.
No clinically signifi cant safety fi ndings for clinical 
laboratory parameters, vital signs, or ECG results 
(including corrected QT interval) were observed after 
treatment with ozanezumab. The frequency of disease-
related events was slightly higher in the ozanezumab 
group (123 [81%] patients) than in the placebo group 
(111 [74%] patients), mainly because of diff erences in the 
frequency of respiratory, thoracic, and mediastinal 
disorders (60 [39%] vs 44 [29%]). A slightly higher frequency 
of psychiatric disorders was reported in the ozanezumab 
group (23 [15%]) than in the placebo group (17 [11%]), 
mainly because of diff erences in the frequency of insomnia 
(six [4%] vs one [1%]). 20 (13%) patients in the ozanezumab 
group and 12 (8%) patients in the placebo group reported 
disease-related weight loss. More possible suicidality-
related adverse events were recorded in the ozanezumab 
group (four [3%]) than in the placebo group (one [1%]).
15 (10%) patients in the ozanezumab group tested 
positive for anti-ozanezumab antibodies after the 
baseline assessment. One of these patients tested positive 
for neutralising anti-ozanezumab antibodies, but this 
patient did not show any evidence of adverse events 
related to immunogenicity (eg, hypersensitivity and rash) 
or any eff ect on effi  cacy or pharmacokinetics.
Discussion
In this phase 2 study, ozanezumab did not show any 
evidence of effi  cacy—instead, the primary outcome and 
all secondary effi  cacy outcomes showed small, non-
signifi cant diff erences in favour of placebo. However, 
ozanezumab was generally well tolerated; rates of adverse 
events, serious adverse events, and adverse events 
leading to permanent discontinuation of study drug or 
withdrawal from the study were similar in the 
ozanezumab and placebo groups.
These fi ndings are surprising because results from 
previous studies8,9,19 had suggested a link between 
Nogo-A and ALS, illustrated by the upregulation of 
Nogo-A in the skeletal muscle of patients and its relation 
with disease severity. Although Nogo-A overexpression 
was also seen in skeletal muscle in other neuromuscular 
diseases, leading to suggestions that this might be a 
non-specifi c marker of denervation,20,21 in patients with 
pure lower motor neuron syndrome, Nogo-A expression 
in skeletal muscle tissue predicted conversion to ALS 
with 91% accuracy, 94% sensitivity, and 88% specifi city.19 
In ALS, neuromuscular junction destabilisation and 
neurite retraction have been suggested to precede 
degeneration of spinal motor neurons (ie, the so-called 
dying-back phenomenon).22 Studies in mice supported a 
potential role for Nogo-A in this process. In the SOD1G86R 
mouse model of ALS, Nogo-A expression was 
upregulated in skeletal muscle before the onset of the 
phenotypic manifestations and was associated with an 
increase in markers of denervation, whereas genetic 
ablation of Nogo-A attenuated this denervation and 
extended the survival of the mice.11 In wild-type mice, 
ectopic overexpression of Nogo-A in the skeletal muscle 
was associated with degeneration of the neuromuscular 
junction and retraction of the nerve terminal.11 These 
fi ndings led to the therapeutic hypothesis that blockade 
of Nogo-A signalling could prevent motor neuron loss 
in ALS.9,11 In a preclinical study,15 ozanezumab resulted 
in a dose-dependent decrease or reversal of neurite 
outgrowth inhibition in a rat postnatal cerebellar 
granular neuron culture. Furthermore, the murine 
parent antibody of ozanezumab had a positive eff ect in 
the SOD1G93A transgenic mouse model of ALS, in which 
it improved spinal motor neuron and motor unit 
survival, increased skeletal muscle force,10 and 
signifi cantly delayed the time to symptom onset 
(assessed as magnitude of motor defi cit compared with 
vehicle controls) and time to death (unpublished). In 
these studies, antibody treatment at an early 
symptomatic stage (70 days after birth) led to signifi cant 
functional benefi ts and a slight reduction in markers of 
muscle denervation at the late symptomatic stage of 
90 days, although many of these diff erences were not 
maintained by day 120.10 In a subsequent fi rst-in-human 
study,12 ozanezumab was well tolerated, and although 
the study was not designed to assess effi  cacy, results for 
Placebo group Ozanezumab group Ozanezumab vs placebo* 
(95% CI)
p value 
Joint-rank score (primary outcome)†
n 151 152 ¨ ¨
Adjusted mean 15·0 (13·6) –14·9 (13·5) –30·0 (–67·9 to 7·9) 0·12
Change from baseline in ALSFRS-R total score
On-treatment data
n 104 101 ¨ ¨
Adjusted mean −9·1 (0·6) −10·4 (0·6) −1·3 (−3·1 to 0·4) 0·14
Including retrieved follow-up data
n 120 111 ¨ ¨
Adjusted mean −9·5 (0·7) −10·8 (0·7) −1·3 (−3·2 to 0·6) 0·17
Monthly rate of decline in ALSFRS-R total score (on-treatment data)
n 149 150 ¨ ¨
Adjusted mean −0·84 (0·06) −0·96 (0·06) −0·12 (−0·30 to 0·05) 0·17
Change in slow vital capacity, L 
n 96 98 ¨ ¨
Adjusted mean −0·90 (0·08) −1·03 (0·08) −0·13 (−0·35 to 0·10) 0·27
Change in hand-held dynamometry (%) 
n‡ 99 95 ¨ ¨
Adjusted mean −34·7% (3·8) −42·9% (3·8) −8·2% (−18·7 to 2·3) 0·13
Data are adjusted mean (SE), unless specifi ed otherwise. ALSFRS-R=Amyotrophic Lateral Sclerosis Functional Rating 
Scale-Revised. *Least squares mean diff erence. †Data collected within 21 days of the patient’s last infusion. ‡Patients 
with non-missing/non-zero measurements at baseline. 
Table 2: Primary and secondary effi  cacy endpoints at week 48
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functional endpoints (such as ALSFRS-R and slow vital 
capacity) and manual muscle testing were numerically 
in favour of ozanezumab at the highest dose of 15 mg/kg 
compared with placebo. Taken collectively, the results 
of these studies were deemed suffi  cient to initiate a 
phase 2 study.
The results of our study, although negative, are robust. 
The study population was representative of patients with 
mild to moderate ALS who had concomitant medical 
disorders that were expected for this population. 
Demographic and baseline characteristics were similar 
between the two treatment groups, and the functional 
decline observed in the placebo group was similar to that 
reported in other clinical studies of ALS.16 A further 
strength is that the study had an independent data-
monitoring committee in place for the periodic review of 
safety and effi  cacy data, and was done in accordance with a 
two-part design to ensure patient safety because the dosing 
regimen used had not been tested in humans previously.
Based on modelling done with preclinical and clinical 
data from previous studies, the dosing regimen used in 
this study was predicted to achieve at least 90% co-
localisation of ozanezumab with Nogo-A, which was 
anticipated to achieve a relevant pharmacodynamics 
eff ect.14 Plasma concentrations of ozanezumab during 
the study confi rmed that the targeted level of exposure to 
ozanezumab was achieved and maintained over the 
duration of dosing, suggesting that dosing was optimum. 
Furthermore, riluzole concentrations were consistent 
with those reported previously,23,24 remained consistent 
over the duration of ozanezumab dosing, and were 
generally similar for both treatment groups, suggesting 
that no pharmacokinetic interaction existed between 
ozanezumab and riluzole.
The primary endpoint was a combined analysis of the 
two key aspects of ALS progression—namely, functional 
decline and survival—which was intended to address the 
limitations of these endpoints when used individually. 
Survival as an endpoint is robust and reliably determined, 
but potentially less sensitive than functional endpoints 
and so would require studies with longer duration or 
larger sample sizes.25 However, analysis of functional 
endpoints can be confounded by missing data due to 
deaths during the treatment period. The analysis of the 
combined survival and functional endpoint used in this 
study is based on a method described by Finkelstein and 
Schoenfeld,25 and can be considered as an analysis of the 
ALSFRS-R with an adjustment for missing data due to 
mortality.18 Combined analysis overcomes problems with 
missing functional data owing to death or study dropouts 
that are not adequately addressed using standard 
techniques for the analysis of function.18
One limitation of this combined endpoint is that it is 
diffi  cult to interpret clinically, and analyses of the data 
for function and survival components are required to 
understand the specifi c clinical eff ects of the study 
drug. Consequently, the component data were analysed 
individually as secondary endpoints. Another limitation 
of this study is the absence of a pharmacodynamic 
marker to confi rm engagement of ozanezumab at 
the target.
Placebo group 
(n=151)
Ozanezumab 
group (n=152)
All adverse events 139 (92%) 140 (92%)
Serious adverse events 46 (30%) 47 (31%)
Deaths
Anytime after randomisation 16 (11%)* 20 (13%)*
During reporting period of 
serious adverse events
13 (9%) 18 (12%)
Drug-related serious adverse events 3 (2%) 3 (2%)
Adverse events leading to 
permanent discontinuation of study 
drug or withdrawal from study
18 (12%) 19 (13%)
*Three deaths in the placebo group and two deaths in the ozanezumab group 
occurred outside the data collection timeframe for serious adverse events 
specifi ed in the protocol (ie, after follow-up contact); no serious adverse events 
were reported in the fi ve patients who died. 
Table 3: Summary of adverse events
Figure 2: (A) Adjusted mean change from baseline in ALSFRS-R total score and (B) overall survival
Error bars represent 95% CI. ALSFRS-R=Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised.
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The lack of effi  cacy in this study contrasts with eff ects 
observed with the murine parent antibody of ozanezumab 
in the SOD1 mouse model of ALS.10 Although this animal 
model of ALS is commonly used, no clinical translation 
has yet been shown.26,27 Riluzole showed mixed results in 
this model, although this was subsequent to demonstration 
of effi  cacy in clinical studies.26,28 The main advantages of 
the SOD1 mouse model are its pathological and phenotypic 
similarities with human ALS, its well established 
endpoints, and the existing guidelines on experimental 
design and methods.29,30 The major limitation of the model 
relates to the inherent diff erences between the mouse 
model and human disease.1,29 For example, disease onset 
and progression are typically more heterogeneous and less 
aggressive in human ALS than in the SOD1 mouse 
model.1,29 Furthermore, mutations in the SOD1 gene are 
estimated to account for only around 2% of ALS cases, and 
SOD1-related ALS do not have the TDP-43 pathology 
associated with most forms of the disease.1,29,30 Highly 
penetrant human SOD1 mutations (eg, Ala4Val) do not 
induce the disease phenotype in the mouse model.29 
Finally, unlike in ALS clinical trials, treatment in SOD1 
mutant mice is often administered before symptom 
onset.1,29 Although preclinical models such as the SOD1 
mouse can provide valuable information on the 
pharmacology of a new investigational drug, fi ndings have 
not translated to the clinical setting so far.26,27 One possible 
approach to address this issue could be, with appropriate 
justifi cation by preclinical pharmacology and safety data, 
to conduct early small experimental medicine clinical 
studies in a well defi ned patient subset (eg, in patients with 
predictors of fast disease progression), using robust 
endpoints with clear success criteria. Evidence of the 
therapeutic target engagement (in preclinical models and 
then in early clinical studies) is also necessary before 
progressing to a clinical effi  cacy study. Clearly, advancing 
the understanding of ALS pathophysiology and natural 
history—including disease modelling, development, and 
validation of reliable biomarkers, and more sensitive 
clinical endpoints—would increase likelihood of a 
successful translation into the clinic.
In this study, more deaths occurred in the ozanezumab 
group than in the placebo group (20 [13%] patients vs 
16 [11%] patients at week 60), and all other effi  cacy 
endpoints showed small, non-signifi cant numerical 
diff erences in favour of placebo. These fi ndings could 
refl ect a possible negative eff ect of ozanezumab. The 
pathogenesis of ALS is still poorly understood, and 
although upregulation of Nogo-A has been associated 
with ALS, this fi nding might refl ect a compensatory 
(rather than disease-causing) role for Nogo-A in human 
disease. If this is the case, it could explain the potential 
worsening eff ect observed with ozanezumab in this 
study. Alternatively, blockade of Nogo-A at the 
neuromuscular junction by ozanezumab could lead to 
enhanced sprouting by increasing the metabolic demand 
on the motor neuron.
However, since the eff ect in favour of placebo was not 
signifi cant, another argument could be that targeting of 
Nogo-A had no eff ect. The diff erences in survival 
observed between groups could refl ect natural variability 
in the rate of disease progression in patients with ALS 
(although disease onset, diagnosis characteristics, and 
phenotype were similar at baseline). Mortality in both 
groups was predominantly driven by respiratory failure, 
which is a common complication associated with disease 
progression and the main cause of death in patients with 
ALS.30 Furthermore, Nogo-A overexpression previously 
observed in patients with ALS could be a downstream 
event in the disease process. This notion is supported by 
reports suggesting that Nogo-A overexpression in skeletal 
muscle might be a non-specifi c marker of denervation 
present in a range of neuromuscular disorders.20,21 In this 
scenario, blockade of Nogo-A would not be expected to 
translate into clinical benefi t, which is consistent with 
the results observed in our study.
Therefore, the mechanism of Nogo-A blockade has been 
comprehensively tested for ALS. In our study, ozanezumab 
did not show any evidence of effi  cacy over placebo for the 
treatment of ALS, and the results suggest the futility of 
further clinical testing of an anti-Nogo-A monoclonal 
antibody for the treatment of ALS.
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